Key clinical point: Out of many associations between sickle cell trait (SCT) and clinical outcomes in the medical literature, only a few were supported by strong evidence.
Major finding: Risks of 1.57-fold and higher were seen in high-quality studies linking SCT to venous and renal complications, while studies of moderate quality suggested small absolute risks of exertion-related mortality or rhabdomyolysis.
Study details: A systematic review including 41 mostly population-based cohort or case-control studies looking at 24 clinical outcomes of interest.
Disclosures: Support for the study came in part from the National Human Genome Research Institute and the National Heart, Lung, and Blood Institute. The authors reported disclosures related to Novartis, Addmedica, and Global Blood Therapeutics, among others.
Naik RP et al. Ann Intern Med. 2018 Oct 30. doi:10.7326/M18-1161.